ArticleThe AAPS journal2010
Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.
Article in The AAPS journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 70 citations in OpenAlex.
- Natural peptidoglycan nanoparticles enable rapid antigen purification and potent delivery of plant-derived vaccines.Plant communications · 2025Article
- Immunomodulatory effects of gut microbiota on vaccine efficacy against respiratory pathogens.Frontiers in immunology · 2025Review
- Oral Immunisation With Non-GMO Surface Displayed SARS-CoV-2 Spike Epitopes on Bacteria-Like Particles Provokes Robust Humoral and Cellular Immune Responses, and Modulated the Gut Microbiome in Mice.Microbial biotechnology · 2025Article
- Gram-positive enhancer matrix delivering FVpE via M cell targeting elicit protective mucosal and adaptive immune responses againstFrontiers in immunology · 2025Article
- The Mechanisms and Application Value of Postbiotics in Caries Prevention and Management.Oral health & preventive dentistry · 2024Review
- A gram-positive enhancer matrix particles vaccine displaying swine influenza virus hemagglutinin protects mice against lethal H1N1 viral challenge.Frontiers in immunology · 2024Article
- A novel bacterium-like particles platform displaying antigens by new anchoring proteins induces efficacious immune responses.Frontiers in microbiology · 2024Article
- Development and Immunoprotection of Bacterium-like Particle Vaccine against Infectious Bronchitis in Chickens.Vaccines · 2023Article
- Bacterium-like particles derived from probiotics: progress, challenges and prospects.Frontiers in immunology · 2023Review
- Alginate as a Promising Biopolymer in Drug Delivery and Wound Healing: A Review of the State-of-the-Art.International journal of molecular sciences · 2022Review
- Oral Vaccination with Hepatitis E Virus Capsid Protein and Immunobiotic Bacterium-Like Particles Induce Intestinal and Systemic Immunity in Mice.Probiotics and antimicrobial proteins · 2020Article
- Article
- Immunomodulatory Properties of Bacterium-Like Particles Obtained From Immunobiotic Lactobacilli: Prospects for Their Use as Mucosal Adjuvants.Frontiers in immunology · 2020Article
- Article
- Preparation, characterization andAsian journal of pharmaceutical sciences · 2019Article
- Article
- Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments.Human vaccines & immunotherapeutics · 2019Article
- Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines.Journal of immunology research · 2019Review
- Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections.Frontiers in immunology · 2019Review
- Passive inhalation of dry powder influenza vaccine formulations completely protects chickens against H5N1 lethal viral challenge.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasal administration of influenza vaccine has the potential to facilitate influenza control and prevention. However, when administered intranasally (i.n.), commercially available inactivated vaccines only generate systemic and mucosal immune responses if strong adjuvants are used, which are often associated with safety problems. We describe the successful use of a safe adjuvant Gram-positive enhancer matrix (GEM) particles derived from the food-grade bacterium Lactococcus lactis for i.n. vaccination with subunit influenza vaccine in mice. It is shown that simple admixing of the vaccine with the GEM particles results in a strongly enhanced immune response. Already after one booster, the i.n. delivered GEM subunit vaccine resulted in hemagglutination inhibition titers in serum at a level equal to the conventional intramuscular (i.m.) route. Moreover, i.n. immunization with GEM subunit vaccine elicited superior mucosal and Th1 skewed immune responses compared to those induced by i.m. and i.n. administered subunit vaccine alone. In conclusion, GEM particles act as a potent adjuvant for i.n. influenza immunization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.